Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 19, 2016. The document serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) rather than a financial results report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting a specific share transaction.
Material Changes and Transaction Details
The filing discloses an increase in the notional interest in Ordinary Shares for Sir Andrew Witty, CEO of GSK. The transaction occurred on July 14, 2016, resulting from the re-investment of dividends paid on shares held in the Company's 2009 Performance Share Plan.
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882)
- Transaction Price: £16.285 per share
- Aggregated Volume: 17,475.826 shares
- Transaction Type: Initial notification of dividend re-investment
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory disclosure of a PDMR transaction.
Investor Verification Checklist
- Verify the total number of shares held by Sir Andrew Witty following this transaction.
- Confirm the terms of the 2009 Performance Share Plan regarding dividend re-investment.
- Check the market price of GSK Ordinary Shares on July 14, 2016, to validate the reported transaction price of £16.285.